Lonza Reaffirmed at Outperform as RBC Notes Tight Supply, Demand in Biologics
() -- RBC Capital Markets reiterated its outperform rating on Lonza Group (LONN.SW) as it updated its biological manufacturing capacity model for contract development and manufacturing organizations and pharmaceutical companies over the next five years. "Lonza sits at the CDMO peer median on 2027E EV/EBITDA despite bei